Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences

08 Apr 2024
www.biospace.com
Phase 1Immunotherapy
↵ Dr. Anthony Johnson, President and Chief Executive Officer of Domain Therapeutics, and Sean A. MacDonald, Chief Business Officer to engage in key industry events in Q2 2024 Domain’s leadership will provide a corporate overview including advancements of key drug candidates in immuno-oncology: DT-9081 currently in Phase I ascending dose, as well as DT-7012 and DT-9045 in IND-enabling studies STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)-- Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024: This press release features multimedia. View the full release here: ​ Anthony Johnson & Sean A. MacDonald (Photo: Domain Therapeutics) Bloom Burton & Co. Healthcare Investor Conference – April 16-17 Location: Metro Toronto Convention Centre (North Building), Toronto, Canada Presentation slot: Wednesday, April 17, 3:30 PM ET, Room 104 A LSX World Congress – April 29-30 Location: Business Design Centre, London, UK Bio€quity Europe – May 12-14 Location: Kursaal Elkargunea Center, San Sebastián, Spain Presentation slot: to be announced at a later date The portfolio currently boasts the following novel drug candidates in the rapidly evolving cancer field of resistance in the tumor micro-environment: DT-7012, a best-in-class Treg-depleting anti-CCR8 monoclonal antibody DT-9045, a first-in-class, PAR2 biased ligand Negative Allosteric Modulator, small molecule DT-9081, an EP4R antagonist program, small molecule currently in Phase I ascending dose study About Domain Therapeutics For more information, please visit: ​ View source version on businesswire.com: Contacts For more information or to schedule a meeting with Dr. Tony Johnson: ICR Consilium Amber Fennell, Namrata Taak, Andrew Stern Email: DomainTherapeutics@consilium-comms.com Tel: +44 (0)20 3709 5813 Source: Domain Therapeutics Smart Multimedia Gallery ​ ​ Photo Anthony Johnson & Sean A. MacDonald (Photo: Domain Therapeutics) ​ ​ Logo ​ View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.